Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CUSTOMIZE: Implementation of Cabotegravir + Rilpivirine LA in the US
NCT04001803Phase 3Completed
- Sponsor
- ViiV Healthcare
- Start
- Jul 2019
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cabotegravir, rilpivirine in human immunodeficiency virus type 1 infection (HIV-1), sponsored by ViiV Healthcare. Started Jul 2019; status: completed.
02
Drugs
cabotegravirrilpivirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04001803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04001803.